Stuart D Russell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7714751/publications.pdf

Version: 2024-02-01

102 papers 12,317 citations

38 h-index 96 g-index

102 all docs

102 docs citations

102 times ranked

9526 citing authors

#	Article	IF	CITATIONS
1	Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist Device. New England Journal of Medicine, 2009, 361, 2241-2251.	27.0	2,813
2	Use of a Continuous-Flow Device in Patients Awaiting Heart Transplantation. New England Journal of Medicine, 2007, 357, 885-896.	27.0	1,619
3	The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: Executive summary. Journal of Heart and Lung Transplantation, 2013, 32, 157-187.	0.6	1,225
4	Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: Incidence, risk factors, and effect on outcomes. Journal of Thoracic and Cardiovascular Surgery, 2010, 139, 1316-1324.	0.8	837
5	Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. Journal of Heart and Lung Transplantation, 2010, 29, S1-S39.	0.6	798
6	Exercise Increases Age-Related Penetrance and Arrhythmic Risk in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy–Associated Desmosomal Mutation Carriers. Journal of the American College of Cardiology, 2013, 62, 1290-1297.	2.8	553
7	Continuous Flow Left Ventricular Assist Device Improves Functional Capacity and Quality of Life of Advanced Heart Failure Patients. Journal of the American College of Cardiology, 2010, 55, 1826-1834.	2.8	540
8	Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. European Heart Journal, 2015, 36, 847-855.	2.2	338
9	Pre-Operative Risk Factors of Bleeding and Stroke During Left Ventricular Assist Device Support. Journal of the American College of Cardiology, 2014, 63, 880-888.	2.8	203
10	Renal and Hepatic Function Improve in Advanced Heart Failure Patients During Continuous-Flow Support With the HeartMate II Left Ventricular Assist Device. Circulation, 2009, 120, 2352-2357.	1.6	186
11	Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials. Journal of Clinical Oncology, 2010, 28, 3416-3421.	1.6	183
12	Variables Measured During Cardiopulmonary Exercise Testing as Predictors of Mortality in Chronic Systolic Heart Failure. Journal of the American College of Cardiology, 2016, 67, 780-789.	2.8	157
13	The Diastolic Pulmonary Gradient DoesÂNot Predict Survival in Patients WithÂPulmonary Hypertension Due to LeftÂHeartÂDisease. JACC: Heart Failure, 2015, 3, 9-16.	4.1	151
14	Endomyocardial Biopsy Characterization of HeartÂFailure With Preserved EjectionÂFraction and Prevalence of Cardiac Amyloidosis. JACC: Heart Failure, 2020, 8, 712-724.	4.1	138
15	Evaluation of the Role of Endomyocardial Biopsy in 851 Patients With Unexplained Heart Failure From 2000–2009. Circulation: Heart Failure, 2013, 6, 676-684.	3.9	125
16	Quality of life and functional status in patients surviving 12 months after left ventricular assist device implantation. Journal of Heart and Lung Transplantation, 2010, 29, 278-285.	0.6	106
17	Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction. JACC: Heart Failure, 2016, 4, 559-566.	4.1	102
18	Fatigability, Exercise Intolerance, and Abnormal Skeletal Muscle Energetics in Heart Failure. Circulation: Heart Failure, 2017, 10, .	3.9	101

#	Article	IF	Citations
19	Recurrence of Cardiac Sarcoidosis in a Heart Transplant Recipient. Journal of Heart and Lung Transplantation, 2005, 24, 1988-1990.	0.6	90
20	Guidance for Timely and Appropriate Referral of Patients With Advanced Heart Failure: A Scientific Statement From the American Heart Association. Circulation, 2021, 144, e238-e250.	1.6	89
21	Right ventricular afterload sensitivity dramatically increases after left ventricular assist device implantation: A multi-center hemodynamic analysis. Journal of Heart and Lung Transplantation, 2016, 35, 868-876.	0.6	76
22	Effect of increasing pump speed during exercise on peak oxygen uptake in heart failure patients supported with a continuousâ€flow left ventricular assist device. A doubleâ€blind randomized study. European Journal of Heart Failure, 2014, 16, 403-408.	7.1	74
23	Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. Journal of Heart and Lung Transplantation, 2017, 36, 380-385.	0.6	69
24	Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. Blood Advances, 2018, 2, 1633-1644.	5.2	66
25	New York Heart Association functional class predicts exercise parameters in the current era. American Heart Journal, 2009, 158, S24-S30.	2.7	65
26	MELD-XI Score Predicts Early Mortality in Patients After Heart Transplantation. Annals of Thoracic Surgery, 2015, 100, 1737-1743.	1.3	65
27	Macrophages and cardiac fibroblasts are the main producers of eotaxins and regulate eosinophil trafficking to the heart. European Journal of Immunology, 2016, 46, 2749-2760.	2.9	62
28	Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a) Tj ETQq0 0 0 rg	BT /Overlo 2.7	ock 10 Tf 50 38 60
29	Racial disparities in the rate of cardiotoxicity of HER2â€targeted therapies among women with early breast cancer. Cancer, 2018, 124, 1904-1911.	4.1	59
30	Temporal Trends in Prevalence and Prognostic Implications of Comorbidities Among Patients With Acute Decompensated Heart Failure. Circulation, 2020, 142, 230-243.	1.6	59
31	Cardiotoxicity From Human Epidermal Growth Factor Receptorâ€2 (HER2) Targeted Therapies. Journal of the American Heart Association, 2017, 6, .	3.7	58
32	Efficacy of Intravenous Furosemide VersusÂa Novel, pH-Neutral Furosemide Formulation Administered SubcutaneouslyÂin Outpatients With Worsening HeartÂFailure. JACC: Heart Failure, 2018, 6, 65-70.	4.1	55
33	Evaluation of Structural Progression in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. JAMA Cardiology, 2017, 2, 293.	6.1	53
34	Heart Failure Is Common and Under-Recognized in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. Circulation: Heart Failure, 2017, 10, .	3.9	53
35	Advanced Heart Failure: A Call to Action. Congestive Heart Failure, 2008, 14, 316-321.	2.0	51
36	Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. Heart, 2016, 102, 303-312.	2.9	50

#	Article	IF	CITATIONS
37	HeartMate < sup> \hat{A}^{\otimes} < /sup>II continuous-flow left ventricular assist system. Expert Review of Medical Devices, 2011, 8, 11-21.	2.8	44
38	Functional Status in Left Ventricular Assist Device–Supported Patients: A Literature Review. Journal of Cardiac Failure, 2014, 20, 973-983.	1.7	39
39	Pump speed modulations and sub-maximal exercise tolerance in left ventricular assist device recipients: A double-blind, randomized trial. Journal of Heart and Lung Transplantation, 2017, 36, 36-41.	0.6	38
40	Survival After Orthotopic Heart Transplantation in Patients Undergoing Bridge to Transplantation With the HeartWare HVAD Versus the Heartmate II. Annals of Thoracic Surgery, 2017, 103, 1505-1511.	1.3	34
41	Acute kidney injury and 1-year mortality after left ventricular assist device implantation. Journal of Heart and Lung Transplantation, $2018, 37, 116-123$.	0.6	33
42	Right-Sided Cardiac Dysfunction in Heart Failure With Preserved Ejection Fraction and Worsening Renal Function. American Journal of Cardiology, 2017, 120, 274-278.	1.6	31
43	Randomized Evaluation of HeartÂFailureÂWith Preserved EjectionÂFractionÂPatients With AcuteÂHeart Failure and Dopamine. JACC: Heart Failure, 2018, 6, 859-870.	4.1	31
44	Impact of the New Pulmonary Hypertension Definition on Heart Transplant Outcomes. Chest, 2020, 157, 151-161.	0.8	31
45	Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock. American Heart Journal, 2018, 199, 181-191.	2.7	30
46	Lack of Relationship Between Serum Cardiac Troponin I Level and Giant Cell Myocarditis Diagnosis and Outcomes. Journal of Cardiac Failure, 2016, 22, 583-585.	1.7	28
47	A Contemporary Analysis of Heart Transplantation and Bridge-to-Transplant Mechanical Circulatory Support Outcomes in Cardiac Sarcoidosis. Journal of Cardiac Failure, 2018, 24, 384-391.	1.7	27
48	Social Support Moderates the Relationship Between Perceived Stress and Quality of Life in Patients With a Left Ventricular Assist Device. Journal of Cardiovascular Nursing, 2018, 33, E1-E9.	1.1	27
49	Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866). Blood, 2015, 126, 4250-4250.	1.4	27
50	Outcomes and Worsening Renal Function in Patients Hospitalized With Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2015, 116, 1534-1540.	1.6	26
51	Outcomes in Patients Bridged With Univentricular and Biventricular Devices in the Modern Era of Heart Transplantation. Annals of Thoracic Surgery, 2016, 102, 102-108.	1.3	24
52	Race- and Gender-Based Differences inÂCardiac Structure and Function andÂRisk of HeartÂFailure. Journal of the American College of Cardiology, 2022, 79, 355-368.	2.8	24
53	Stage A Heart Failure Is Not Adequately Recognized in US Adults: Analysis of the National Health and Nutrition Examination Surveys, 2007-2010. PLoS ONE, 2015, 10, e0132228.	2.5	23
54	Mechanistic Insights into Sympathetic Neuronal Regeneration. Circulation: Cardiovascular Imaging, 2015, 8, e003507.	2.6	23

#	Article	IF	CITATIONS
55	Patients Commonly Believe Their Heart Failure Hospitalizations Are Preventable and Identify Worsening Heart Failure, Nonadherence, and a Knowledge Gap as Reasons for Admission. Journal of Cardiac Failure, 2017, 23, 252-256.	1.7	22
56	A Comprehensive Risk Score to Predict Prolonged Hospital Length of Stay After Heart Transplantation. Annals of Thoracic Surgery, 2018, 105, 83-90.	1.3	22
57	Impact of Continuous Flow Left Ventricular Assist Device Therapy on Chronic Kidney Disease: A Longitudinal Multicenter Study. Journal of Cardiac Failure, 2020, 26, 333-341.	1.7	22
58	Exercise Heart Rates in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2015, 115, 1144-1150.	1.6	21
59	Usefulness of Coronary Artery Calcium to Predict Heart Failure With Preserved Ejection Fraction in Men Versus Women (from the Multi-Ethnic Study of Atherosclerosis). American Journal of Cardiology, 2017, 120, 1847-1853.	1.6	21
60	Predictors of Mortality by Sex and Race in Heart Failure With Preserved Ejection Fraction: ARIC Community Surveillance Study. Journal of the American Heart Association, 2020, 9, e014669.	3.7	19
61	Does Recipient Age Impact Functional Outcomes of Orthotopic Heart Transplantation?. Annals of Thoracic Surgery, 2014, 97, 1636-1642.	1.3	18
62	Incidence and early outcomes associated with pre-transplant antivimentin antibodies in the cardiac transplantation population. Clinical Transplantation, 2015, 29, 685-688.	1.6	17
63	Endothelial Stromal PD-L1 (Programmed Death Ligand 1) Modulates CD8 ⁺ T-Cell Infiltration After Heart Transplantation. Circulation: Heart Failure, 2021, 14, e007982.	3.9	17
64	Effect of Age and Renal Function on Survival After Left Ventricular Assist Device Implantation. American Journal of Cardiology, 2017, 120, 2221-2225.	1.6	16
65	The influence of institutional volume on the incidence of complications and their effect on mortality after heart transplantation. Journal of Heart and Lung Transplantation, 2015, 34, 1390-1397.	0.6	15
66	Quality of life and treatment preference for ventricular assist device therapy in ambulatory advanced heart failure: A report from the REVIVAL study. Journal of Heart and Lung Transplantation, 2020, 39, 27-36.	0.6	15
67	Arginine vasopressin as a target in the treatment of acute heart failure. World Journal of Cardiology, 2014, 6, 1252.	1.5	13
68	Baseline Characteristics Predict the Presence of Amyloid on Endomyocardial Biopsy. Journal of Cardiac Failure, 2017, 23, 340-344.	1.7	12
69	SSRI/SNRI Therapy is Associated With a Higher Risk of Gastrointestinal Bleeding in LVAD Patients. Heart Lung and Circulation, 2020, 29, 1241-1246.	0.4	12
70	Vasopressin Receptor Antagonists. American Journal of Cardiovascular Drugs, 2003, 3, 13-20.	2.2	11
71	Sympathectomy for Stabilization of Heart Failure Due to Drug-Refractory Ventricular Tachycardia. Annals of Thoracic Surgery, 2018, 105, e51-e53.	1.3	11
72	Effect of Heart Rate Reserve on Exercise Capacity in Patients Treated with a Continuous Left Ventricular Assist Device. ASAIO Journal, 2020, 66, 160-165.	1.6	11

#	Article	IF	CITATIONS
73	The predictors of post-transplant coronary events among liver transplant recipients. Hepatology International, 2016, 10, 974-982.	4.2	10
74	Usefulness of Pulse Amplitude Changes During the Valsalva Maneuver Measured Using Finger Photoplethysmography to Identify Elevated Pulmonary Capillary Wedge Pressure in Patients With Heart Failure. American Journal of Cardiology, 2017, 120, 966-972.	1.6	10
75	Long-term Follow-up of Continuous Flow Left Ventricular Assist Devices: Complications and Predisposing Risk Factors. International Journal of Artificial Organs, 2017, 40, 622-628.	1.4	10
76	Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic. American Heart Journal, 2021, 233, 122-131.	2.7	10
77	Increased lipofuscin on endomyocardial biopsy predicts greater cardiac improvement in adolescents and young adults. Cardiovascular Pathology, 2012, 21, 317-323.	1.6	9
78	Patient selection for mechanical circulatory support. Heart Failure Reviews, 2013, 18, 27-34.	3.9	9
79	One-and-done: Do left ventricular assist device patients on the transplant list really need frequent right heart catheterization assessments for pulmonary hypertension?. Journal of Heart and Lung Transplantation, 2015, 34, 1637-1639.	0.6	9
80	Tonapofylline: a selective adenosine-1 receptor antagonist for the treatment of heart failure. Expert Opinion on Pharmacotherapy, 2010, 11, 2405-2415.	1.8	8
81	Cancer Survivorship and Subclinical Myocardial Damage. American Journal of Epidemiology, 2019, 188, 2188-2195.	3.4	8
82	Usefulness of Noninvasively Measured Pulse Amplitude Changes During the Valsalva Maneuver to Identify Hospitalized Heart Failure Patients at Risk of 30-Day Heart Failure Events (from the) Tj ETQq0 0 0 rgBT /	Overlock 1	.0 Tef 50 377 T
83	Progression of aortic valve insufficiency during centrifugal versus axial flow left ventricular assist device support. European Journal of Cardio-thoracic Surgery, 2022, 61, 1188-1196.	1.4	8
84	Outcomes and predictors of recovery in acute-onset cardiomyopathy: A single-center experience of patients undergoing endomyocardial biopsy for new heart failure. American Heart Journal, 2016, 179, 116-126.	2.7	7
85	Physiological and Psychological Stress in Patients Living With a Left Ventricular Assist Device. ASAIO Journal, 2018, 64, e172-e180.	1.6	7
86	The ABCs of managing systolic heart failure: Past, present, and future. Cleveland Clinic Journal of Medicine, 2016, 83, 753-765.	1.3	7
87	Acute cardiovascular hospitalizations and illness severity before and during the <scp>COVID</scp> â€19 pandemic. Clinical Cardiology, 2021, 44, 656-664.	1.8	6
88	Transcriptomic Analysis Identifies the Effect of Beta-Blocking Agents on a Molecular Pathway of Contraction in the Heart and Predicts Response to Therapy. JACC Basic To Translational Science, 2016, 1, 107-121.	4.1	5
89	Racial Differences and Temporal Obesity Trends in Heart Failure with Preserved Ejection Fraction. Journal of the American Geriatrics Society, 2021, 69, 1309-1318.	2.6	4
90	Cardiovascular adverse events in the drugâ€development program of bupropion for smoking cessation: A systematic retrospective adjudication effort. Clinical Cardiology, 2017, 40, 899-906.	1.8	3

#	ARTICLE	IF	CITATIONS
91	Biomarkers in Advanced Heart Failure. Circulation: Heart Failure, 2020, 13, e006840.	3.9	3
92	Acute Diuretic-Sparing Effects of Sacubitril-Valsartan: Staying in the Loop. Journal of Pharmacy Practice, 2022, 35, 859-863.	1.0	3
93	Candidate Selection for Long-Term Left Ventricular Assist Device Therapy for Advanced Heart Failure. , 2012, , 72-87.		3
94	Nonplatelet thromboxane generation is associated with impaired cardiovascular performance and mortality in heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2022, 323, H248-H255.	3.2	3
95	Response to Letters Regarding Article, "Electrocardiographic Features of Arrhythmogenic Right Ventricular Dysplasiaâ€, Circulation, 2010, 121, .	1.6	1
96	Cardiac Allograft Vasculopathy: What We Know in 2016. Current Transplantation Reports, 2016, 3, 175-184.	2.0	1
97	Predicting Prognosis in Heart Failure. JACC: Heart Failure, 2018, 6, 754-756.	4.1	1
98	Can We Now Find the Needle in the Haystack? â^—. JACC: Heart Failure, 2014, 2, 474-476.	4.1	0
99	Clinical Trial Results in Mechanical Circulatory Support. , 2020, , 175-188.		0
100	Pericardial Adipose Tissue Volume and Left Ventricular Assist Device-Associated Outcomes. Journal of Cardiac Failure, $2021, , .$	1.7	0
101	Abstract 18178: Cardiac Index Declines During Long-term LVAD Support. Circulation, 2014, 130, .	1.6	0
102	Preoperative patient optimization for mechanical circulatory support. Annals of Cardiothoracic Surgery, 2014, 3, 626-9.	1.7	0